Alectinib in combination with bevacizumab as first-line treatment in ALK -rearranged non-small ce...

Alectinib in combination with bevacizumab as first-line treatment in ALK -rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial  Nature

Alectinib causes sinus bradycardia by suppressing L-type calcium current in sinus node - ScienceD...

Alectinib causes sinus bradycardia by suppressing L-type calcium current in sinus node  ScienceDirect.com

Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC - CancerNetwork

Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC  CancerNetwork

Development of a Scalable Manufacturing Process for Alectinib with a Concise Preparation of the I...

Development of a Scalable Manufacturing Process for Alectinib with a Concise Preparation of the Indole-Containing Tetracyclic Core  ACS Publications

Perforation of the descending colon induced by alectinib in a patient with non-small cell lung ca...

Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report  Frontiers

ALNEO Phase II Trial Highlights Promising Role of Perioperative Alectinib in Stage III Resectable...

ALNEO Phase II Trial Highlights Promising Role of Perioperative Alectinib in Stage III Resectable ALK-Positive NSCLC  Oncodaily

CROWN Trial 5-Year Update: Lorlatinib Is the Frontrunner in the Frontline Setting - ASCO Daily News

CROWN Trial 5-Year Update: Lorlatinib Is the Frontrunner in the Frontline Setting  ASCO Daily News

Dr Horinouchi on Safety Data for Adjuvant Alectinib in ALK+ NSCLC - OncLive

Dr Horinouchi on Safety Data for Adjuvant Alectinib in ALK+ NSCLC  OncLive

Full article: Nanovector approach for co-delivery of Alectinib and Hesperidin via inhalational fo...

Full article: Nanovector approach for co-delivery of Alectinib and Hesperidin via inhalational for lung cancer treatment: development, characterization, and preclinical studies  Taylor & Francis Online: Peer-reviewed Journals

Lorlatinib overcomes alectinib-induced hemolytic anemia in an ALK fusion positive non-small-cell ...

Lorlatinib overcomes alectinib-induced hemolytic anemia in an ALK fusion positive non-small-cell lung cancer patient with severe tumor-associated liver failure: A case report  Wiley Online Library

CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resist...

CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resistant to alectinib  Nature

Development of a Scalable Manufacturing Process for Alectinib with a Concise Preparation of the I...

Development of a Scalable Manufacturing Process for Alectinib with a Concise Preparation of the Indole-Containing Tetracyclic Core  ACS Publications

Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC - Oncod...

Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC  Oncodaily

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in ...

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient  Frontiers

Exploring First-Line ALK Inhibitors, TKI Sequencing in ALK-Positive NSCLC - CancerNetwork

Exploring First-Line ALK Inhibitors, TKI Sequencing in ALK-Positive NSCLC  CancerNetwork

Nanovector approach for co-delivery of Alectinib and Hesperidin via inhalational for lung cancer ...

Nanovector approach for co-delivery of Alectinib and Hesperidin via inhalational for lung cancer treatment: development, characterization, and preclinical studies  Taylor & Francis Online: Peer-reviewed Journals

Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management - OncLive

Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management  OncLive

Brigatinib vs alectinib in crizotinib-refractory advanced ALK+ NSCLC by James Chih-Hsin Yang et a...

Brigatinib vs alectinib in crizotinib-refractory advanced ALK+ NSCLC by James Chih-Hsin Yang et al.  Oncodaily

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-pos...

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer  Nature

Barend Sikkema: Body weight gain associated with alectinib in patients with ALK positive NSCLC - ...

Barend Sikkema: Body weight gain associated with alectinib in patients with ALK positive NSCLC  Oncodaily

Combining Avastin With Alecensa Shows Promise in Advanced ALK-Positive Lung Cancer - Managed Heal...

Combining Avastin With Alecensa Shows Promise in Advanced ALK-Positive Lung Cancer  Managed Healthcare Executive

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma ...

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib  Frontiers

258 HORIZON-01: a phase I–III platform study evaluating the efficacy and safety of multiple thera...

258 HORIZON-01: a phase I–III platform study evaluating the efficacy and safety of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non-small cell lung cancer (NSCLC)  ScienceDirect.com

Greenness assessment and stability-indicating LC method for determination of alectinib using Box-...

Greenness assessment and stability-indicating LC method for determination of alectinib using Box-Behnken design, high-resolution mass spectrometric identification, and molecular docking studies of its novel degradation products  ScienceDirect.com

of alectinib in patients with ALK -positive advanced - researchgate.net

of alectinib in patients with ALK -positive advanced  researchgate.net

Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib...

Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib  Wiley Online Library

Coexistence of a novel SV2B-ALK EML4-ALK double-fusion in a lung poorly differentiated adenocarci...

Coexistence of a novel SV2B-ALK EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review  Frontiers

Chemometrically assisted optimization and validation of the HPLC method for the analysis of alect...

Chemometrically assisted optimization and validation of the HPLC method for the analysis of alectinib and its related impurity with measurement uncertainty evaluation and whiteness, blueness, and greenness profile assessments  BMC Chemistry

Greenness assessment and stability-indicating LC method for determination of alectinib using Box-...

Greenness assessment and stability-indicating LC method for determination of alectinib using Box-Behnken design, high-resolution mass spectrometric identification, and molecular docking studies of its novel degradation products  ScienceDirect.com

FDA Approves Alectinib for ALK-Positive Lung Cancer - National Cancer Institute (.gov)

FDA Approves Alectinib for ALK-Positive Lung Cancer  National Cancer Institute (.gov)

Case report: Metastatic Colorectal Cancer with ALK-CEP44 Fusion and Rapid Resistance Development ...

Case report: Metastatic Colorectal Cancer with ALK-CEP44 Fusion and Rapid Resistance Development Response to Alectinib in Metastatic Colorectal Cancer with multiple and functionally unclear ALK alterations -A Case Report  Frontiers

Nuvalent Launches Head-to-Head Phase 3 Trial Against Leading Lung Cancer Drug, Plus New HER2 Stud...

Nuvalent Launches Head-to-Head Phase 3 Trial Against Leading Lung Cancer Drug, Plus New HER2 Study  Stock Titan

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer - The New England Journal of Medicine

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer  The New England Journal of Medicine

Fig 1: Inhibitory role of Alectinib on EML4-ALK positive NSCLC and... - researchgate.net

Fig 1: Inhibitory role of Alectinib on EML4-ALK positive NSCLC and...  researchgate.net

General structures of alectinib, JH-VII-139-1 and c(RGDyK) peptide conjugates that carry an SRPK1...

General structures of alectinib, JH-VII-139-1 and c(RGDyK) peptide conjugates that carry an SRPK1 inhibitor.  researchgate.net

Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Foll...

Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up  JACC

Alectinib Reduces Risk of Recurrence or Death by 76% in Early-Stage, Resected, ALK+ NSCLC - Oncol...

Alectinib Reduces Risk of Recurrence or Death by 76% in Early-Stage, Resected, ALK+ NSCLC  Oncology Nursing News

European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment f...

European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer  Roche

Epithelioid inflammatory myofibroblastic sarcoma treated with Alectinib: a case report and litera...

Epithelioid inflammatory myofibroblastic sarcoma treated with Alectinib: a case report and literature review  Frontiers

ALK -rearranged Non–Small Cell Lung Cancer Cystic Brain Metastases - RSNA Journals

ALK -rearranged Non–Small Cell Lung Cancer Cystic Brain Metastases  RSNA Journals

Adjuvant Alectinib Earns European Approval in Resectable ALK+ NSCLC - CancerNetwork

Adjuvant Alectinib Earns European Approval in Resectable ALK+ NSCLC  CancerNetwork

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicent...

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study  BMC Medicine

Neoadjuvant Therapy Trumps Surgery in NSCLC Debate - CancerNetwork

Neoadjuvant Therapy Trumps Surgery in NSCLC Debate  CancerNetwork

Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positi...

Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positive non-small cell lung carcinoma: a case report  Journal of Medical Case Reports

Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-posit...

Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer  Wiley Online Library

FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer - National Cancer Instit...

FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer  National Cancer Institute (.gov)

ALK Inhibitors Market: A Comprehensive Overview of Current Trends and Future Projections | DelveI...

ALK Inhibitors Market: A Comprehensive Overview of Current Trends and Future Projections | DelveInsight  PR Newswire

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunit...

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity  Nature

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer - The New Engla...

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer  The New England Journal of Medicine

Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC - CancerNetwork

Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC  CancerNetwork

Discovery of orally bioavailable ALK PROTACs based ceritinib against ALK positive cancers - Scien...

Discovery of orally bioavailable ALK PROTACs based ceritinib against ALK positive cancers  ScienceDirect.com

Alectinib-induced rash unresponsive to desensitization: a case report and literature review - BMC...

Alectinib-induced rash unresponsive to desensitization: a case report and literature review  BMC Pulmonary Medicine

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC - OncLive

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC  OncLive

Alectinib “First of Many Approvals” In ALK+ NSCLC - CancerNetwork

Alectinib “First of Many Approvals” In ALK+ NSCLC  CancerNetwork

High incidence and reversible bradycardia events following alectinib initiation - Yuan - 2023 - T...

High incidence and reversible bradycardia events following alectinib initiation - Yuan - 2023 - Thoracic Cancer  Wiley Online Library

Brigatinib, Alectinib Produce Similar PFS After NSCLC Progression on Crizotinib - Cancer Therapy ...

Brigatinib, Alectinib Produce Similar PFS After NSCLC Progression on Crizotinib  Cancer Therapy Advisor

Eosin‐5‐maleimide (EMA) binding study results of the patient receiving... - researchgate.net

Eosin‐5‐maleimide (EMA) binding study results of the patient receiving...  researchgate.net

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptot...

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation  Nature

Alectinib Approved for ALK-Positive Adjuvant NSCLC - Medscape

Alectinib Approved for ALK-Positive Adjuvant NSCLC  Medscape

Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell ly...

Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial  Wiley Online Library

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable...

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer  Frontiers

Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1 - Nature

Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1  Nature

Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinas...

Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report  Baishideng Publishing

Alecensa (alectinib): Side effects, dosage, and more - Medical News Today

Alecensa (alectinib): Side effects, dosage, and more  Medical News Today

Adjuvant Alectinib Gets FDA Priority Review for Early-Stage ALK+ NSCLC - Oncology Nursing News

Adjuvant Alectinib Gets FDA Priority Review for Early-Stage ALK+ NSCLC  Oncology Nursing News

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-sma...

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer  Frontiers

An investigation into solubility and dissolution improvement of alectinib hydrochloride as a thir...

An investigation into solubility and dissolution improvement of alectinib hydrochloride as a third-generation amorphous solid dispersion  ScienceDirect.com

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming cl...

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance  ScienceDirect.com

Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer - Na...

Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer  Nature

Choosing Between ALK Inhibitors in the Treatment of NSCLC - OncLive

Choosing Between ALK Inhibitors in the Treatment of NSCLC  OncLive

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK pos...

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)  Frontiers

UV spectrum of the compound Alectinib calculated by TDB3LYP/6-31G* method - researchgate.net

UV spectrum of the compound Alectinib calculated by TDB3LYP/6-31G* method  researchgate.net

Alectinib Yields Better Overall Survival Than Ceritinib in ALK-Positive Non–Small Cell Lung Cance...

Alectinib Yields Better Overall Survival Than Ceritinib in ALK-Positive Non–Small Cell Lung Cancer  CancerNetwork

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma | npj Precision...

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma | npj Precision Oncology  Nature

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC - MedPage Today

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC  MedPage Today

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive ...

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study  The Lancet

Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK ...

Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK -positive non-small-cell lung cancer  Wiley Online Library

Treatment Options for Patients with ALK+ NSCLC who Progress on First-line TKIs - Targeted Oncology

Treatment Options for Patients with ALK+ NSCLC who Progress on First-line TKIs  Targeted Oncology

Adjuvant Alectinib Could Aid Disease-Free Survival in ALK-Positive NSCLC - Pharmacy Times

Adjuvant Alectinib Could Aid Disease-Free Survival in ALK-Positive NSCLC  Pharmacy Times

Crystal structure of alectinib hydrochloride Type I, C30H35N4O2Cl | Powder Diffraction - Cambridg...

Crystal structure of alectinib hydrochloride Type I, C30H35N4O2Cl | Powder Diffraction  Cambridge University Press & Assessment

For Alecensa, ‘Take With Meal’ May Have a Caveat - Managed Healthcare Executive

For Alecensa, ‘Take With Meal’ May Have a Caveat  Managed Healthcare Executive

The Downfall of Consolidation Immunotherapy and Rise of Targeted Therapy in Unresectable Stage II...

The Downfall of Consolidation Immunotherapy and Rise of Targeted Therapy in Unresectable Stage III NSCLC With EGFR and ALK Alterations  ASCO Daily News

ALINA Trial: Adjuvant Alectinib Improves Survival vs Platinum-Based Chemotherapy in ALK -Positive...

ALINA Trial: Adjuvant Alectinib Improves Survival vs Platinum-Based Chemotherapy in ALK -Positive NSCLC  The ASCO Post

Figure 2. X-ray powder diffraction patterns of crystalline Type I... - researchgate.net

Figure 2. X-ray powder diffraction patterns of crystalline Type I...  researchgate.net

Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers - Cancer Therapy Ad...

Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers  Cancer Therapy Advisor

A New Molecularly Targeted Therapy for Lung Cancer - American Association for Cancer Research (AACR)

A New Molecularly Targeted Therapy for Lung Cancer  American Association for Cancer Research (AACR)

Roche wins second FDA label expansion for Alecensa in NSCLC - Pharmaceutical Technology

Roche wins second FDA label expansion for Alecensa in NSCLC  Pharmaceutical Technology

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an...

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial  The Lancet

FDA Approves Alectinib for ALK-Positive Non-Small Cell Lung Cancer - National Cancer Institute (....

FDA Approves Alectinib for ALK-Positive Non-Small Cell Lung Cancer  National Cancer Institute (.gov)

Full article: Alectinib for Treatment of ALK-Positive Non-Small-Cell Lung Cancer - Taylor & Franc...

Full article: Alectinib for Treatment of ALK-Positive Non-Small-Cell Lung Cancer  Taylor & Francis Online: Peer-reviewed Journals

FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type o...

FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer  Roche

The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive cr...

The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China  Frontiers

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK -rearranged non-sm...

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK -rearranged non-small cell lung cancer  Wiley Online Library

Dramatic response to alectinib in a patient with ALK -rearranged squamous cell lung cancer - Wile...

Dramatic response to alectinib in a patient with ALK -rearranged squamous cell lung cancer  Wiley Online Library

Diet May Have Big Effect on Common Lung Cancer Treatment - Inside Precision Medicine

Diet May Have Big Effect on Common Lung Cancer Treatment  Inside Precision Medicine

Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Foll...

Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up  JACC

FDA Approves Alectinib to Treat ALK-positive Lung Cancer - respiratory-therapy.com

FDA Approves Alectinib to Treat ALK-positive Lung Cancer  respiratory-therapy.com

ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage...

ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage ALK+ NSCLC  OncLive

Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and...

Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report  Frontiers

ALK fusions in the pan-cancer setting: another tumor-agnostic target? | npj Precision Oncology - ...

ALK fusions in the pan-cancer setting: another tumor-agnostic target? | npj Precision Oncology  Nature